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Abstract
Granulocytic sarcoma is an extramedullary tumor composed of leukemic blasts. Isolated granulocytic sarcoma has rarely 
been reported in children with leukemia undergoing allogeneic stem cell transplantation. We report a case of isolated 
granulocytic sarcoma arising from the pleura in an 11-year-old girl who was previously treated for biphenotypic leukemia 
with allogeneic stem cell transplantation. Complete resolution of the tumor was achieved after two inductions with MRC 
12 protocol; however, she died of sepsis during the neutropenic period. The unusual presentation, immunophenotypic 
differences at diagnosis and relapse, and the management options are discussed. (Turk J Hematol 2009; 26: 151-3)
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Özet
Granulositik sarkom, lösemik blastların oluşturduğu ekstrameduller bir tümördür. İzole granulositik sarkom, allogeneik kök 
hücre nakli yapılan lösemili çocuklarda nadiren bildirilmiştir. Bifenotipik lösemi relapsı nedeni ile allogeneik kök hücre nakli 
ile tedavi edilen ve izleminde plevra kaynaklı izole granulositik sarkom gelişen 11 yaşındaki kız olgu sunulmuştur. MRC 12 
protokolüne göre iki indüksiyon tedavisi sonrası granulositik sarkomu tamamen kaybolan olgu, nötropenik dönemde 
gelişen sepsis nedeni ile kaybedilmiştir. Granulositik sarkomlu bu olguda olağandışı yerleşim, tanı ve relapsta immunfeno-
tipik farklılık ve tedavi yaklaşımları tartışılmıştır. (Turk J Hematol 2009; 26: 151-3)
Anahtar kelimeler: İzole granulositik sarkom, kök hücre nakli, relaps
Geliş tarihi: 09 Ağustos 2008       Kabul tarihi: 24 Aralık 2008Introduction
Granulocytic sarcoma (GS) is a solid tumor composed of 
leukemic myeloblasts and partially matured granulocytes [1]. GS 
may be the initial manifestation of myeloproliferative disorders, 
and the appearance of the disease in the marrow and blood may 
follow weeks or months later without treatment. It usually occurs 
in association with acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML) and myelodysplastic syndrome (MDS) at 
diagnosis. The lesions may be found in any location, especially 
skin, orbita, nasal sinuses, bone, pleura, and other sites [2]. 
Prognosis and treatment are poor when GS occurs after stem 
cell transplantation (SCT) [3]. 
We report a child with biphenotypic leukemia who relapsed 
as a GS in the pleura 12 months after allogeneic SCT. 
Case Report
An 11-year-old girl presented with cough, chest and bone 
pain of one-month duration. On physical examination, there was 
no other pathological finding rather than diminished breath 
sounds in the left lung. Laboratory investigations including blood 
count, urine analysis, and blood chemistry were also normal 
except anemia. Chest X-ray showed extensive pleural effusion 
filling the left lung. Histopathological analysis of the pleural speci-
men without immunophenotyping of the effusion material, which 
was performed in another center before referral to our hospital, 
strongly suggested infiltration predominantly by lymphoblasts. 
Her bone marrow also had abundant blastic infiltration. 
Immunophenotypic analysis was found to be positive for 67% 
CD13, 72% CD33, 76% CD19, 74% CD22, and 78% HLA-DR 
and negative for CD3, CD5, CD7, CD10 and cytoplasmic myelo-
peroxidase (c-MPO). Cytogenetic analysis of the marrow speci-
men showed normal karyotype and was negative for t (9; 22) and 
t (4; 11), which are the main determinants for risk classification. 
She was diagnosed as myeloid marker-positive acute lympho-
blastic leukemia (My+ALL), and ALL-BFM 95 medium-risk proto-
col was started. Although pleura and bone marrow blasts had 
completely disappeared after induction by day 33, she devel-
oped isolated bone marrow relapse with a normal chest X-ray 
within one year after diagnosis. Immunophenotyping at relapse 
was similar to that of the diagnosis except for c-MPO positivity, 
which is consistent with biphenotypic leukemia. Cytogenetic 
markers for t (9; 22) and t (4; 11) were still negative and second 
remission was achieved after reinduction with ALL-BFM 95 high-
risk (HR) protocol. According to the BFM-95 HR protocol, after 
three blocks following induction therapy she received HLA identi-
cal SCT from her sibling male donor and subsequent condition-
ing with busulfan, cyclophosphamide and etoposide. A bone 
marrow with a cellular content of CD34: 4.6 x 106 cell/kg was 
infused without any manipulation. Cyclosporine (CSA) and 
methotrexate were used for graft versus host disease (GVHD) 
prophylaxis. Neutrophil count > 0.5x109 /L was reached on the 
17th day and platelet count > 20,000/mm3 was reached on the 
30th day. On the 40th day, she developed a stage 3 acute GVHD 
in skin and stage 2 in gut, which was treated by CSA and steroid 
for three months. The patient was not on the immunosuppressive 
therapy at the time of relapse. One year after transplant, she 
presented with isolated leukemic infiltrates in the left pleura, while 
her marrow showed no sign of the disease with a 100% donor 
chimerism. Histopathological and immunohistochemical exami-
nation revealed that the mass was a GS in which MPO, CD43, 
CD56, CD68, and CD117 positivity were depicted on tumor cells 
with no CD3 or CD20 (Figure 1 A-C). After two induction chemo-
therapy with MRC–12 AML protocol, the leukemic mass gradu-
ally decreased (Figure 2 A, B). However, she died of gram-nega-
tive sepsis during the neutropenic phase of the second induction 
therapy.  
Discussion 
Isolated GS has rarely been reported in children undergoing 
allogeneic SCT for leukemia. The European Bone Marrow 
Transplantation (EBMT) Registry reported the incidence of GS to 
be 0.45% in children with myeloid malignancies, which occurred 
within 4 to 56 months after transplantation. It is reported to be 
0.65% in AML and 0.22% in CML and MDS [3]. In children, 
although GS mostly accompanies myeloid malignancies, limited 
data are available in ALL with intracranial and orbital GS [4,5]. GS 
may occur in almost any part of the body but is most common in 
the skin, lymph nodes and bone. As pleural infiltration by leuke-
mic cells following SCT is a rare condition, little is known about 
the treatment and outcome of isolated extramedullary relapse [6]. 
Biphenotypic leukemia, which is a relatively rare type of leu-
kemia, is characterized by the presence of both myeloid and 
lymphoid cell surface antigens. The scoring system proposed by 
the European Group for the Immunological Characterization of 
Leukemia (EGIL) is useful for this purpose [7]. However, it is dif-
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Figure 1. A. Tumoral infiltrate composed of blastic cells with narrow cytoplasm, round to oval nuclei and prominent small nucleoli displaying open chromatin pattern 
(hematoxylin-eosin, x400); B. Blastic cells show CD43 positivity (CD43, x400); C. Blastic cells show focal MPO positivity (MPO, x400)
A       B       Cficult to differentiate MPO-negative cases of biphenotypic leuke-
mia, and a few cases may be misinterpreted. In addition, immu-
nological changes between initial diagnosis and relapse have 
also been reported, which might be due to the gain or loss of 
aberrant markers at relapse causing clonal instability of leukemic 
cell [8-10]. We also found immunophenotypic differences 
between initial diagnosis and relapse. Though all the published 
cases of mediastinal GS have relapsed, immunophenotypic dif-
ferences between primary leukemia with My+ALL and recurrent 
leukemia with GS have not been well documented in children 
[11]. There are also no uniform criteria or any consensus on the 
treatment of these cases [12].
The management of cases with GS after SCT is controversial. 
Although the EBMT Registry included several treatment strate-
gies like chemotherapy, radiotherapy, surgery, donor lymphocyte 
infusion, and second transplant, the optimal therapeutic approach 
remains unclear. It is well established that the graft versus leuke-
mia (GVL) effect plays a substantial role in the prevention of leu-
kemia relapse after SCT. It has been reported that the GVL effect 
is dependent upon GVHD in the setting of HLA identical sibling 
SCT [13]. Despite the full chimerism and the presence of GVHD, 
an isolated extramedullary relapse after transplantation occurred 
in our case. Possible mechanisms of extramedullary relapse that 
have been suggested are the inefficiency of GVL or chemothera-
py in extramedullary sites compared with bone marrow [14,15]. 
Moreover, a full chimerism status may not be predictive of 
absence of minimal residual disease and it also does not appear 
to protect from extramedullary relapse [16].   
 In summary, although pleural GS with or without concurrent 
myeloid malignancy is well described, similar clinical findings in 
the presence of My+ALL or biphenotypic leukemia are not 
known. Immunophenotypic changes during the progression of 
leukemia could well be a marker of more resistant disease. In our 
case, GS disappeared after two induction chemotherapy regi-
mens; we could not determine the long-term prognosis because 
the patient died of sepsis. Long-term studies are required to 
ascertain the appropriate treatment and prognosis of isolated GS 
after SCT.   
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Figure 2. A. Axial CT scan showing a large pleural-based soft tissue lesion with 
regular contours in the upper lobe of the left lung; B. Control CT examination shows 
a significant decrease in the size of the lesion 
A      B